Opinion|Videos|March 13, 2025
Clinical Insights and Patient Considerations for Frontline TKI Therapy in Advanced uHCC
Author(s)Amit Mahipal, MD
An expert discusses how treatment selection for first-line (1L) tyrosine kinase inhibitor (TKI) therapy in advanced hepatocellular carcinoma (HCC) requires careful evaluation of multiple factors, including liver function (Child-Pugh status), ECOG performance status, tumor burden, and presence of macrovascular invasion or extrahepatic spread. In reviewing individual cases, clinicians assess liver enzyme levels, α-fetoprotein values, radiographic findings, and comorbidities.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- From your clinical experience, how do you determine which patients are best suited for 1L systemic TKI therapy for advanced unresectable HCC (uHCC)?
- What factors/details from the patient case (history/diagnostics) are notable?
- What factors do you consider most when making treatment decisions, and how do those factors influence your treatment approach?
- How do you determine which patients would benefit from lenvatinib or sorafenib?
Advertisement
Related to this article
The FDA assigned an April 9, 2027, PDUFA date to rivoceranib plus camrelizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
2
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
3
Oncologists Discuss Ibrutinib Switching and Fixed-Duration Therapy in CLL
4
Novocure’s Optune Mya Gets FDA Not Approvable Letter
5